Personalized Neoantigen Cancer Vaccine Development Reduced to 4 Weeks
A New York based precision cancer immunotherapy company announced it has reduced the timeline from biopsy to vaccine to under 4 weeks for its personalized neoantigen therapeutic cancer vaccines.
Announced on March 26, 2020, EpiVax Oncology, Inc.’s CEO and Co-Founder, Gad Berdugo, MSc Eng., MBA, stated in a press release, ”This will enable our precision immunotherapy to treat patients in the neoadjuvant clinical setting before surgical removal of their tumors, potentially improving the patient’s clinical outcome.”
“Personalized cancer vaccines are created based on information obtained from an individual’s tumor. Previously, the process to create a personalized vaccine starting from tumor biopsy took at least 12 to 18 weeks.”
EpiVax Oncology's personalized vaccine design platform, Ancer, incorporates the world-class EpiMatrix® system and the innovative JanusMatrix tool, which were exclusively licensed to EpiVax Oncology by EpiVax.
Ancer is designed to enable the rapid discovery of highly immunogenic neoantigens for precision cancer immunotherapy.
EpiVax’s neo-peptides are patient-specific peptides that are designed using Ancer®: EpiVax Oncology’s advanced in-silico neoantigen prediction platform powered by machine learning-based algorithms that have been refined over more than 20 years.
Arjun Balar, MD, Associate Professor of Medicine, Director Genitourinary Medical Oncology Program, NYU Laura and Isaac Perlmutter Cancer Center, NYU Langone Health said, “Patients with metastatic disease cannot wait for effective therapy. Moreover, a rapid biopsy to vaccine administration time opens the door to presurgical or neoadjuvant “window of opportunity” studies.”
“This is something that has long been missing in previous approaches to cancer vaccines.”
EpiVax Oncology, Inc. is a privately-held biotechnology company focusing on developing precision cancer immunotherapies based in New York City, NY.
Cancer vaccine development news published by Vax-Before-Cancer.